JORGE E CORTES to Biomarkers, Pharmacological
This is a "connection" page, showing publications JORGE E CORTES has written about Biomarkers, Pharmacological.
Connection Strength
0.230
-
Switching to nilotinib versus imatinib dose escalation in patients with chronic myeloid leukaemia in chronic phase with suboptimal response to imatinib (LASOR): a randomised, open-label trial. Lancet Haematol. 2016 Dec; 3(12):e581-e591.
Score: 0.139
-
Monitoring molecular response in chronic myeloid leukemia. Cancer. 2011 Mar 15; 117(6):1113-22.
Score: 0.091